| Course | NU 670 Advanced Psychopharmacology and Health Promotion |
|---|---|
| Unit | Unit 2 |
| Paper type | Clearance pathway table |
| Length | About 670 words, 5 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN Psychiatric Mental Health Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NU 670 Unit 2
Clearance Pathway Table for Eight Psychotropic Agents: What Removes Each One, What Each One Does to Others, and What Shifts Levels
Student Name
Department of Nursing, Herzing University
NU 670: Advanced Psychopharmacology and Health Promotion
Instructor Name
January 28, 2026
Clearance Pathway Table for Eight Psychotropic Agents: What Removes Each One, What Each One Does to Others, and What Shifts Levels
Purpose
This table records, for eight psychotropic agents commonly prescribed in outpatient psychiatric practice, the main route by which each is cleared, whether the agent itself inhibits or induces a clearance pathway, and what commonly raises or lowers its levels. It is organized by pathway rather than by drug class, because interactions follow pathways. The content follows standard psychopharmacology references and reviews of antipsychotic interactions (Stahl, 2021; Spina & de Leon, 2007); prescribers should confirm details in current prescribing information before acting.
The Table
The table groups agents by the pathway that clears them.
| Agent | Main clearance route | Does it inhibit or induce? | Commonly raises levels | Commonly lowers levels |
|---|---|---|---|---|
| Olanzapine | Hepatic CYP1A2; direct glucuronidation (UGT1A4) | No meaningful effect | Fluvoxamine; ciprofloxacin; stopping smoking | Smoking; carbamazepine |
| Clozapine | Hepatic CYP1A2, with minor CYP3A4 and CYP2C19 | No meaningful effect | Fluvoxamine; ciprofloxacin; stopping smoking; inflammation or infection | Smoking; carbamazepine |
| Quetiapine | Hepatic CYP3A4 | No meaningful effect | Ketoconazole; clarithromycin; grapefruit in large amounts | Carbamazepine; phenytoin; rifampin |
| Aripiprazole | Hepatic CYP2D6 and CYP3A4 | No meaningful effect | Strong CYP2D6 inhibitors such as fluoxetine and paroxetine; strong CYP3A4 inhibitors | Carbamazepine and other strong CYP3A4 inducers |
| Fluoxetine | Hepatic CYP2D6 and others; active metabolite norfluoxetine | Strong CYP2D6 inhibitor; moderate CYP2C19 inhibitor; effect persists weeks after stopping | CYP2D6 poor metabolizer status | Little of clinical importance |
| Sertraline | Hepatic, several CYP enzymes | Mild to moderate CYP2D6 inhibition, greater at higher doses | Few clinically important | Carbamazepine; rifampin |
| Lamotrigine | Hepatic glucuronidation (UGT1A4) | No meaningful effect | Valproate, which roughly doubles levels | Carbamazepine; phenytoin; estrogen-containing contraceptives; pregnancy |
| Lithium | Renal excretion, unchanged | None | NSAIDs; ACE inhibitors; angiotensin receptor blockers; thiazide diuretics; dehydration; low sodium intake | Pregnancy; high sodium intake; theophylline |
Reading the Table by Pathway
CYP1A2 agents, olanzapine and clozapine. Cigarette smoke, through the polycyclic aromatic hydrocarbons it contains, induces CYP1A2. A meta-analysis found substantially lower concentrations of both drugs in smokers than in non-smokers (Tsuda et al., 2014). The clinical consequence runs both ways: a smoker who quits, or is admitted to a smoke-free hospital, can see levels rise considerably within days. For clozapine, whose toxicity includes seizures, this is among the most important interactions in psychiatry. Nicotine replacement does not induce CYP1A2; the inducing agents are in the smoke, not the nicotine.
CYP3A4 agents, quetiapine and, in part, aripiprazole. Strong inducers such as carbamazepine can lower quetiapine levels so much that it becomes ineffective, while strong inhibitors raise levels.
CYP2D6 agents and inhibitors, aripiprazole with fluoxetine or paroxetine. Fluoxetine and paroxetine are strong CYP2D6 inhibitors, and aripiprazole's labeling recommends reducing its dose when combined with a strong CYP2D6 inhibitor. Because norfluoxetine has a long half-life, fluoxetine's inhibition persists for weeks after it is stopped, which matters when switching.
Glucuronidation, lamotrigine. Valproate inhibits lamotrigine's glucuronidation and roughly doubles its levels, which is why lamotrigine is started at a lower dose and titrated more slowly with valproate, to reduce the risk of serious rash. Estrogen induces the same pathway, so starting or stopping an estrogen-containing contraceptive changes lamotrigine levels.
Renal excretion, lithium. Lithium is not metabolized; its level depends on the kidney. Anything that reduces renal lithium clearance, including common medications for pain and blood pressure, dehydration, or a low-sodium diet, raises the level, and lithium's therapeutic range is narrow (Grandjean & Aubry, 2009).
The Inducer That Appears in Almost Every Row
Carbamazepine is not one of the eight agents in the table, but it appears in the lowers-levels column for six of them. It is a strong inducer of CYP3A4 and also induces CYP1A2 and glucuronidation, and it induces its own metabolism, so its own half-life shortens over the first weeks of treatment. When carbamazepine is added to a regimen containing quetiapine, aripiprazole, olanzapine, clozapine, sertraline, or lamotrigine, the other drug's level can fall enough to lose effect, and when carbamazepine is stopped, the other drug's level rises again over a few weeks as the induction wears off. Oxcarbazepine induces far less but can still lower levels of estrogen-containing contraceptives, which matters for women taking lamotrigine or planning pregnancy.
Timing of Interactions
Inhibition and induction differ in timing, which affects monitoring. Inhibition usually takes effect within days, as soon as the inhibitor reaches steady state, so a new strong inhibitor calls for early review. Induction develops over one to three weeks, as the body produces more enzyme, and reverses over a similar period after the inducer stops. A patient who stops smoking therefore sees olanzapine or clozapine levels climb over roughly a week or two, which is the window for a follow-up visit or level.
Three Rules for Practice
Ask about smoking at every visit for patients on olanzapine or clozapine, and plan ahead when a patient intends to quit or is admitted. Check for strong CYP2D6 or CYP3A4 inhibitors or inducers before starting aripiprazole or quetiapine, including antibiotics and antifungals started by other prescribers. And for lithium, review every new medication from any prescriber, since the drugs that raise lithium levels are among the most commonly prescribed in primary care.
References
Grandjean, E. M., & Aubry, J.-M. (2009). Lithium: Updated human knowledge using an evidence-based approach: Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs, 23(4), 331-349. https://doi.org/10.2165/00023210-200923040-00005
Spina, E., & de Leon, J. (2007). Metabolic drug interactions with newer antipsychotics: A comparative review. Basic & Clinical Pharmacology & Toxicology, 100(1), 4-22. https://doi.org/10.1111/j.1742-7843.2007.00017.x
Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
Tsuda, Y., Saruwatari, J., & Yasui-Furukori, N. (2014). Meta-analysis: The effects of smoking on the disposition of two commonly used antipsychotic agents, olanzapine and clozapine. BMJ Open, 4(3), Article e004216. https://doi.org/10.1136/bmjopen-2013-004216
NU 670 Unit 2 instructions, in plain terms
In Unit 2 you build a table of how several psychotropic medications are cleared and how they interact. Expect to list each agent's main clearance pathway, the drugs and substances that raise or lower its levels, and the agent's own effect on others, then interpret the table and draw practice rules. Many versions ask you to address timing of interactions and non-drug factors such as smoking. Check how many agents your section wants and whether pharmacogenomic columns are expected. Group agents by pathway so patterns are visible. Include common inducers and inhibitors that patients may take for other conditions, such as antibiotics or anticonvulsants. Cite interaction reviews rather than software output, and explain the clinical significance rather than listing every possible pairing.
How the NU 670 Unit 2 example is put together
The document opens with its purpose and scope in a few lines. The table groups agents by pathway, with columns for what raises levels, what lowers them and what the agent does to others. The reading section moves pathway by pathway, explaining the most important interactions in plain terms, such as smoking and olanzapine. A section singles out carbamazepine because it appears in so many rows, which teaches a pattern rather than a list. The timing section explains when to expect an interaction to show and when to check levels. The rules section turns the table into three habits a prescriber can use at every visit. The format would fit on a clinic wall, which matches the practical purpose.
NU 670 Unit 2 rubric: what full points look like
Herzing's rubric for a clearance table typically covers the accuracy of pathways, the completeness of interacting agents, organization, interpretation, clinical application and writing. Accuracy decides much of the grade, since an error in a pathway leads to wrong predictions downstream. Completeness points reward common inducers and inhibitors, including non-psychiatric drugs and smoking. Organization criteria look for grouping that reveals patterns. Interpretation earns credit when the paper explains significance rather than repeating the table. Clinical application points go to specific practice rules. Timing of induction and inhibition is often scored within interpretation. Spina and de Leon's review and Grandjean and Aubry on lithium appear in the APA 7 list.
NU 670 Unit 2 help: mistakes that cost points
Clearance tables in Unit 2 usually lose points through pathway errors, such as listing a drug under the wrong enzyme. Another frequent problem is leaving out smoking, which matters greatly for CYP1A2 agents. Students often list interactions without saying whether they raise or lower levels. Non-psychiatric drugs are ignored. Timing is not addressed, so the reader does not know when to check. The table is not interpreted. Lithium's renal clearance is treated as if it were hepatic. Finally, draw practice rules from the table, because graders look for a document a prescriber could use, not only an accurate list of enzymes.
Get a NU 670 Unit 2 example written to your instructions
Send the Unit 2 instructions and the rubric from your NU 670 classroom, along with the agents the table should hold. We write a custom example with principal and secondary routes separated, inhibition and induction in their own columns, every shared pair given a direction, and each row sourced to a dated revision. First custom sample free, returned in 24 to 48 hours.
More NU 670 papers and PMHNP samples
- NU 670 Unit 1: Receptor activity brief
- NU 670 Unit 3: Whole regimen interaction screen
- NU 670 Unit 4: Adverse effect derivation record
- NU 670 Unit 5: Metabolic monitoring protocol
- NU 670 Unit 6: Special population handling brief
- NU 670 Unit 7: Lifestyle and psychoeducation package
- NU 670 Unit 8: Regimen lifecycle dossier
- NU 672 Unit 2: Boundary and self-disclosure review
- NU 673 Unit 2: Community resource pathway
- NU 674 Unit 2: Chronic illness trajectory review
- NU 671 Unit 2: Mental status examination record
NU 670 Unit 2 questions, answered
How many agents should the table hold?
Few enough that every row can be sourced and discussed, which usually means four to eight rather than a whole formulary. A short table with real narrative under it outperforms a long one nobody could verify, and the instructions often cap the number anyway. Where a class shares a route, one representative plus a sentence about the class covers more ground than three near-identical rows.
Does the table need pharmacogenomic columns?
Only where the instructions ask for them, and then handled carefully. Naming the enzyme, the direction a variant shifts exposure, and whether testing is routinely available is enough for an academic table. What a result would mean for one person is a clinical judgment resting on current labeling and your own board, and an example is not where that question gets settled.
Do non-psychiatric medicines belong in it?
More often than not, since these routes are shared with cardiac agents, anti-infectives, anticonvulsants and several products sold without a prescription. A table confined to psychotropic pairs misses the overlaps that actually turn up on a medication list. Hold the non-psychiatric rows to the same sourcing standard as the rest, and note where the evidence for one of them is thin.
Where can I find a free NU 670 Unit 2 sample paper?
Read the complete NU 670 Unit 2 clearance table here at no charge, eight agents grouped by pathway with timing notes and practice rules. A table for different agents or with pharmacogenomic columns can be prepared on request.
Why does smoking affect olanzapine and clozapine levels?
Polycyclic aromatic hydrocarbons in tobacco smoke induce CYP1A2, the enzyme that clears both drugs. When a patient quits or is admitted to a smoke-free unit, levels can rise sharply within one to two weeks, which this sample flags as a practice rule.